OC-0634 Lymphocyte Sparing Radiation Therapy for stage III NSCLC: a dosimetric study

Fernandes, P.; Jourani, Y.; Birkfellner, Wolfgang; Charlier, F.; Ferreira, A.; Ven, G. Van de; Moretti, Luigi; Fardeau, E.; Gestel, D. Van; Reynaert, N.

doi:10.1016/s0167-8140(21)06990-5

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to a growing interest for the combination of radiotherapy with immunotherapy, and the impact of one on another, EDIC models were calculated in several studies. Based on these models which are now well established for thoracic and upper abdominal localizations [18] , [40] , [41] , [42] , [43] , [44] , we could propose some explanations to our results. A trial including patients treated for stage III NSCLC reported a median EDIC of 6.1 Gy, which is higher than the EDICs we calculated [43] .…”

Section: Discussionsupporting

confidence: 51%